Non–Small Cell Lung Cancer, Version 6.2015

Cancer statistics, 2015

Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial

Chun, S. G., Hu, C., Choy, H., Komaki, R. U., Timmerman, R. D., Schild, S. E., Bogart, J. A., Dobelbower, M. C., Bosch, W. R., Galvin, J. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1378 · Cited by 747

The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics

Cheng, T. D., Cramb, S. M., Baade, P. D., Youlden, D. R., Nwogu, C. E., & Reid, M. E. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.021 · Cited by 613

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Leighl, N. B., Page, R. D., Raymond, V. M., Daniel, D. B., Divers, S. G., Reckamp, K. L., Villalona-Calero, M. A., Dix, D., Odegaard, J. I., Lanman, R. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0624 · Cited by 593

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., Lieberman, D. B., Morrissette, J. D., Evans, T. L., Bauml, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1231 · Cited by 325

Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery

Chang, J. Y., Mehran, R. J., Feng, L., Verma, V., Liao, Z. X., Welsh, J. W., Lin, S. H., O’Reilly, M. S., Jeter, M. D., Balter, P. A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00401-0 · Cited by 322

Specific Gut Microbiome Signature Predicts the Early-Stage Lung Cancer

Zheng, Y., Fang, Z., Xue, Y., Zhang, J., Zhu, J., Gao, R., Yao, S., Ye, Y., Wang, S., Lin, C., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1737487 · Cited by 301

hsa_circ_0013958: a circular RNA and potential novel biomarker for lung adenocarcinoma

Zhu, X., Wang, X., Wei, S., Chen, Y., Chen, Y., Fan, X., Han, S., & Wu, G. (2017) · FEBS Journal · doi:10.1111/febs.14132 · Cited by 298

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Wu, Y.-L. L. C., Cheng, Y., Zhou, J., Lü, S., Zhang, Y., Zhao, J., Kim, D., Soo, R. A., Kim, S., Pan, H., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30154-5 · Cited by 257

Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

Gutierrez, M. E., Choi, K., Lanman, R. B., Licitra, E. J., Skrzypczak, S. M., Benito, R. P., Wu, T., Arunajadai, S. G., Kaur, S., Harper, H. D., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.004 · Cited by 206

Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11

Fleur, L. L., Falk-Sörqvist, E., Smeds, P., Berglund, A., Sundström, M., Mattsson, J. S., Brandén, E., Koyi, H., Isaksson, J., Brunnström, H., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.003 · Cited by 202

Bevacizumab: A Review of Its Use in Advanced Cancer

Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0302-9 · Cited by 186

Prognostic effect of liver metastasis in lung cancer patients with distant metastasis

Ren, Y., Dai, C., Zheng, H. W., Zhou, F., She, Y., Jiang, G., Fei, K., Yang, P., Xie, D., & Chen, C. (2016) · Oncotarget · doi:10.18632/oncotarget.10644 · Cited by 163

Uncommon EGFR mutations in advanced non-small cell lung cancer

O'Kane, G. M., Bradbury, P. A., Feld, R. D., Leighl, N. B., Liu, G., Pisters, K.-M., Kamel‐Reid, S., Tsao, M., & Shepherd, F. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.016 · Cited by 153

Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment

Mattonen, S. A., Palma, D. A., Johnson, C., Louie, A. V., Landis, M. S., Rodrigues, G., Chan, I. Y. M., Etemad‐Rezai, R., Yeung, T. P. C., Senan, S., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.12.369 · Cited by 141

PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/β-catenin signaling pathway

Zhan, P., Zhang, B., Xi, G., Wu, Y., Liu, H., Liu, Y.-F., Xu, W., Zhu, Q., Cai, F., Zhou, Z., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0682-z · Cited by 140

Emerging landscape of circular RNAs in lung cancer

Hu, W., Bi, Z., Chen, Z., Liu, C., Li, L., Zhang, F., Zhou, Q. Y., Zhu, W., Song, Y., Zhan, B.-T., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.006 · Cited by 135

Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway

Tao, L., Huang, G., Wang, R., Pan, Y., He, Z., Chu, X., Song, H., & Chen, L. (2016) · Scientific Reports · doi:10.1038/srep38408 · Cited by 135

EGFR Kinase Domain Duplication ( EGFR -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

Gallant, J., Sheehan, J. H., Shaver, T. M., Bailey, M., Lipson, D., Chandramohan, R., Brewer, M. R., York, S. J., Kris, M. G., Pietenpol, J. A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0654 · Cited by 128

National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer

Higgins, K. A., O’Connell, K., Liu, Y., Gillespie, T. W., McDonald, M. W., Pillai, R. N., Patel, K. R., Patel, P. R., Robinson, C. G., Simone, C. B., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.10.001 · Cited by 123

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

Yamamoto, N., Seto, T., Nishio, M., Goto, K., Yamamoto, N., Okamoto, I., Yamanaka, T., Tanaka, M., Takahashi, K., & Fukuoka, M. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.020 · Cited by 125

Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer

Vantaku, V., Dong, J., Ambati, C. R., Perera, D. N., Donepudi, S. R., Amara, C. S., Putluri, V., Ravi, S. S., Robertson, M. J., Piyarathna, D. W. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1515 · Cited by 116

SBI0206965, a novel inhibitor of Ulk1, suppresses non-small cell lung cancer cell growth by modulating both autophagy and apoptosis pathways

Tang, F., Hu, P., Yang, Z., Xue, C. H., Gong, J., Sun, S., Liu, S., Zhang, S., Li, Z., Yang, C., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5635 · Cited by 115

Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy

Baik, C. S., Myall, N. J., & Wakelee, H. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0458 · Cited by 114

Targeting HER2 in the treatment of non-small cell lung cancer

Mar, N., Vredenburgh, J. J., & Wasser, J. S. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2014.12.018 · Cited by 102

Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma

Qian, F., Yang, W., Wang, R., Xu, J., Wang, S., Zhang, Y., Jin, B., Yu, K., & Han, B. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.09.143 · Cited by 101

Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis

Sabatini, L. M., Mathews, C., Ptak, D. M., Doshi, S., Tynan, K., Hegde, M., Burke, T. L., & Bossler, A. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.11.010 · Cited by 99

Stereotactic body radiotherapy for oligoprogressive cancer

Cheung, P. (2016) · British Journal of Radiology · doi:10.1259/bjr.20160251 · Cited by 96

Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?

Mino-Kenudson, M. A., & Mino-Kenudson, M. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0009 · Cited by 93

Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes

Chen, H., Yao, W., Chu, Q., Han, R., Wang, Y., Sun, J., Wang, D., Wang, Y., Cao, M., & He, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.08.024 · Cited by 93

Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer

Verma, V., Simone, C. B., Allen, P. K., Gajjar, S., Shah, C., Zhen, W. K., Harkenrider, M. M., Hallemeier, C. L., Jabbour, S. K., Matthiesen, C. L., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.10.041 · Cited by 93

Site‐to‐Site Reproducibility and Spatial Resolution in MALDI–MSI of Peptides from Formalin‐Fixed Paraffin‐Embedded Samples

Ly, A., Longuespée, R., Casadonte, R., Wandernoth, P., Schwamborn, K., Bollwein, C., Marsching, C., Kriegsmann, K., Hopf, C., Weichert, W., et al. (2018) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201800029 · Cited by 92

Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens

Kriegsmann, M., Casadonte, R., Kriegsmann, J., Dienemann, H., Schirmacher, P., Kobarg, J. H., Schwamborn, K., Stenzinger, A., Warth, A., & Weichert, W. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.057513 · Cited by 91

Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma

Yang, C. J., Wang, H., Kumar, A., Wang, X., Hartwig, M. G., D’Amico, T. A., & Berry, M. F. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.07.032 · Cited by 89

Long-term outcomes after lobectomy for non–small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis

Yang, C. J., Kumar, A., Gulack, B. C., Mulvihill, M. S., Hartwig, M. G., Wang, X., D’Amico, T. A., & Berry, M. F. (2015) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2015.12.028 · Cited by 84

CircRNA has_circ_0001946 promotes cell growth in lung adenocarcinoma by regulating miR-135a-5p/SIRT1 axis and activating Wnt/β-catenin signaling pathway

Yao, Y., Hua, Q., Zhou, Y., & Shen, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.120 · Cited by 82

Circular RNA hsa_circ_0000326 acts as a miR-338-3p sponge to facilitate lung adenocarcinoma progression

Xu, Y., Yu, J., Huang, Z., Fu, B., Tao, Y., Qi, X., Mou, Y., Hu, Y., Wang, Y., Cao, Y., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01556-4 · Cited by 80

miR‐134 inhibits non‐small cell lung cancer growth by targeting the epidermal growth factor receptor

Qin, Q., Wei, F., Zhang, J., Wang, X.-W., & Li, B. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12889 · Cited by 76

Phase IB Trial of the Anti‐Cancer Stem Cell DLL4‐Binding Agent Demcizumab with Pemetrexed and Carboplatin as First‐Line Treatment of Metastatic Non‐Squamous NSCLC

McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-017-0543-0 · Cited by 74

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

Kim, S. T., Banks, K. C., Lee, S., Kim, K., Park, J. O., Park, S. H., Park, Y. S., Lim, H. Y., Kang, W. K., Lanman, R. B., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00059 · Cited by 72

The synergistic effect of resveratrol in combination with cisplatin on apoptosis via modulating autophagy in A549 cells

Hu, S., Li, X., Xu, R., Ye, L., Kong, H., Zeng, X., Wang, H., & Xie, W. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw026 · Cited by 71

Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies

Fisher, K. E., Zhang, L., Wang, J., Smith, G. H., Newman, S., Schneider, T. M., Pillai, R. N., Kudchadkar, R. R., Owonikoko, T. K., Ramalingam, S. S., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.11.006 · Cited by 71

Presence of Even a Small Ground-Glass Component in Lung Adenocarcinoma Predicts Better Survival

Berry, M. F., Gao, R. W., Kunder, C. A., Backhus, L. M., Khuong, A., Kadoch, M. A., Leung, A. N. C., & Shrager, J. B. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.020 · Cited by 71

Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features

Khorrami, M., Jain, P., Bera, K., Alilou, M., Thawani, R., Patil, P. D., Ahmad, U., Murthy, S. C., Stephans, K. L., Fu, P., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.020 · Cited by 70

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib

Wang, W., Xu, C., Chen, Y., Liu, W., Zhong, L., Chen, F., Zhuang, W., Huang, Y., Huang, Z., Chen, R., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.04.98 · Cited by 68

p62-Induced Cancer-Associated Fibroblast Activation via the Nrf2-ATF6 Pathway Promotes Lung Tumorigenesis

Kang, J. I., Kim, D. H., Sung, K. W., Shim, S. M., Cha‐Molstad, H., Soung, N., Lee, K. H., Hwang, J., Lee, H. G., Kwon, Y. T., et al. (2021) · Cancers · doi:10.3390/cancers13040864 · Cited by 74

Three Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting NSCLC

Tang, Q., Ni, Z., Cheng, Z., Xu, J., Yu, H., & Yin, P. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430226 · Cited by 69

The resistance mechanisms and treatment strategies for EGFR -mutant advanced non-small-cell lung cancer

Zhong, W., Zhou, Q. H., & Wu, Y.-L. L. C. (2017) · Oncotarget · doi:10.18632/oncotarget.20311 · Cited by 66

Circ-SOX4 drives the tumorigenesis and development of lung adenocarcinoma via sponging miR-1270 and modulating PLAGL2 to activate WNT signaling pathway

Gao, N., & Ye, B. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1065-x · Cited by 65

HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma

Wang, Z., TANG, F., Hu, P., Wang, Y., Gong, J., Sun, S., & Xie, C. (2016) · Oncology Reports · doi:10.3892/or.2016.4811 · Cited by 65

Downregulation of Nrf2 promotes radiation-induced apoptosis through Nrf2 mediated Notch signaling in non-small cell lung cancer cells

Zhao, Q., Mao, A., YAN, J., Sun, C., Di, C., Zhou, X. H., Li, H., Guo, R., & Zhang, H. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3301 · Cited by 63

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer

Yerokun, B. A., Yang, C. J., Gulack, B. C., Li, X., Mulvihill, M. S., Gu, L., Wang, X., Harpole, D. H., D’Amico, T. A., Berry, M. F., et al. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.02.065 · Cited by 61

Surgical treatment for early stage non-small cell lung cancer

Raman, V., Yang, C. J., Deng, J. Z., & D’Amico, T. A. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.172 · Cited by 59

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy

Verstegen, N. E., Lagerwaard, F. J., Hashemi, S. M. S., Dahele, M. R., Slotman, B. J., & Senan, S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000576 · Cited by 58

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations

Passaro, A., Prelaj, A., Bonanno, L., Tiseo, M., Tuzi, A., Proto, C., Chiari, R., Rocco, D., Genova, C., Sini, C., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.005 · Cited by 54

A novel 4-gene signature for overall survival prediction in lung adenocarcinoma patients with lymph node metastasis

Wang, Y., Zhang, Q., Gao, Z., Shan, X., Zhao, Y., Zhang, K., Shi, R., & Bao, X. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0822-1 · Cited by 54

Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy

Leeman, J. E., Rimner, A., Montecalvo, J., Hsu, M., Zhang, Z., von Reibnitz, D., Panchoo, K., Yorke, E. D., Adusumilli, P. S., Travis, W. D., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.09.037 · Cited by 54

Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis

Yang, C. J., Gu, L., Shah, S. A., Yerokun, B. A., D’Amico, T. A., Hartwig, M. G., & Berry, M. F. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.021 · Cited by 54

Overexpression of PEAK1 contributes to epithelial–mesenchymal transition and tumor metastasis in lung cancer through modulating ERK1/2 and JAK2 signaling

Ding, C., Tang, W., Fan, X., Wang, X., Wu, H., Xu, H., Xu, W., Gao, W., & Wu, G. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0817-1 · Cited by 54

Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives

Chen, H., Zhang, T., Wu, Q., Huang, X., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.664290 · Cited by 52

Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: a meta-analysis of incidence of elective nodal failure (ENF)

Li, R., Yu, L., Lin, S., Wang, L., Dong, X., Yu, L., Li, W., & Li, B. (2016) · Radiation Oncology · doi:10.1186/s13014-016-0698-3 · Cited by 52

Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer

Ajmani, G. S., Wang, C., Kim, K. W., Howington, J. A., & Krantz, S. B. (2018) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2018.02.095 · Cited by 52

MiRNA-195-5p Functions as a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1

Zheng, J., Xu, T., Chen, F., & Zhang, Y. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-018-0552-z · Cited by 52

Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation

Binkley, M. S., Hiniker, S. M., Chaudhuri, A. A., Maxim, P. G., Diehn, M., Loo, B. W., & Shultz, D. B. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.12.007 · Cited by 51

The Airway Transcriptome as a Biomarker for Early Lung Cancer Detection

Billatos, E. S., Vick, J. L., Lenburg, M. E., & Spira, A. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3187 · Cited by 51

Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review

Desai, A. P., & Lovly, C. M. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-708 · Cited by 55

Uniportal video-assisted thoracoscopic surgery: safety, efficacy and learning curve during the first 250 cases in Quebec, Canada

Drevet, G., & Ugalde, P. A. (2016) · Annals of Cardiothoracic Surgery · doi:10.21037/acs.2016.03.05 · Cited by 50

Mcl‐1 targeting could be an intriguing perspective to cure cancer

Blasio, A. D., Vento, R., & Fiore, R. D. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26786 · Cited by 55

Pulmonary Sarcomatoid Carcinoma: Experience From SEER Database and Shanghai Pulmonary Hospital

Sun, L., Dai, J., Chen, Y., Duan, L., He, W., Chen, Q., Wang, H., Zhu, Y., Zhang, H., Jiang, G., et al. (2020) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.02.071 · Cited by 50

Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer: a population-based cohort study

You, D., Wang, D., Wu, Y., Chen, X., Shao, F., Wei, Y., Zhang, R., Lange, T., Ma, H., Xu, H., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02400-6 · Cited by 48

Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial

Guberina, M., Eberhardt, W., Stuschke, M., Gauler, T. C., Heinzelmann, F., Cheufou, D. H., Kimmich, M., Friedel, G., Schmidberger, H., Darwiche, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx069 · Cited by 49

Identification of Circulating Long Noncoding RNA Linc00152 as a Novel Biomarker for Diagnosis and Monitoring of Non-Small-Cell Lung Cancer

Li, N., Feng, X., Tan, Q., Luo, P., Wei, J., Zhu, M., Liang, C., Tu, J., & Ning, Y. (2017) · Disease Markers · doi:10.1155/2017/7439698 · Cited by 48

Personalised medicine for nonsmall cell lung cancer

Mascaux, C., Tomasini, P., Greillier, L., & Barlési, F. (2017) · European Respiratory Review · doi:10.1183/16000617.0066-2017 · Cited by 49

Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review

Tomasik, B., Skrzypski, M. T., Bieńkowski, M., Dziadziuszko, R., & Jassem, J. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-742 · Cited by 48

Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma

Hung, J., Wu, Y., Chou, T., Jeng, W., Yeh, Y., & Hsu, W. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.10.075 · Cited by 46

PIK3CA mutations as prognostic factor in squamous cell lung carcinoma

McGowan, M., Silye, A., Lund‐Iversen, M., Solberg, S. K., Helland, Å., Hirsch, F. R., & Brustugun, O. T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.018 · Cited by 46

Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT

Hörner‐Rieber, J., Bernhardt, D., Blanck, O., Duma, M. N., Eich, H. T., Gerum, S., Gkika, E., Hass, P., Henkenberens, C., Herold, H., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.024 · Cited by 43

The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations

Zheng, D., Chen, H., Wang, R., Zhang, Y., Pan, Y., Cheng, X., Cheng, C., Zheng, S., Li, H., Gong, R., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s96834 · Cited by 46

Predicting distant failure in early stage NSCLC treated with SBRT using clinical parameters

Zhou, Z., Folkert, M. R., Cannon, N., Iyengar, P., Westover, K. D., Zhang, Y., Choy, H., Timmerman, R. D., Yan, J., Xie, X.-J., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.04.029 · Cited by 45

Genetic variants in ABCG 1 are associated with survival of nonsmall‐cell lung cancer patients

Wang, Y., Liu, H., Ready, N., Su, L., Wei, Y., Christiani, D. C., & Wei, Q. (2016) · International Journal of Cancer · doi:10.1002/ijc.29991 · Cited by 43

Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer

Li, X., & Zhou, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19007 · Cited by 43

LncRNA MALAT-1 competitively regulates miR-124 to promote EMT and development of non-small-cell lung cancer

Wu, J., Weng, Y., He, F., Liang, D., & Cai, L. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000626 · Cited by 43

The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer

Geva, S., Rozenblum, A. B., Twito, T., Grinberg, R., Dvir, A., Soussan‐Gutman, L., Ilouze, M., Roisman, L. C., Dudnik, E., Zer, A., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.101 · Cited by 43

Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling

Zarif, T. E., Meador, C. B., Qiu, X., Seo, J.-H., Davidsohn, M. P., Savignano, H., Lakshminarayanan, G., McClure, H. M., Canniff, J., Fortunato, B. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0466 · Cited by 42

Comparing the Diagnostic Potential of 68Ga-Alfatide II and 18F-FDG in Differentiating Between Non–Small Cell Lung Cancer and Tuberculosis

Kang, F., Wang, S., Tian, F., Zhao, M., Zhang, M., Wang, Z., Li, G., Liu, C., Yang, W., Li, X., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167924 · Cited by 42

A new tool to predict lung cancer based on risk factors

Ahmad, A. S., & Mayya, A. M. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03402 · Cited by 42

Oncologic Outcomes of Surgery Versus SBRT for Non–Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis

IJsseldijk, M. A., Shoni, M., Siegert, C., Wiering, B., van Engelenburg, A. K. C., Tsai, T. C., ten Broek, R. P. G., & Lebenthal, A. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.04.017 · Cited by 42

Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy

Velez, A., DeMaio, A. J., & Sterman, D. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203539 · Cited by 43

Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB

Luo, J., Huang, Q., Wang, R., Han, B., Zhang, J., Zhao, H., Fang, W., Luo, Q., Yang, J., Yang, Y., et al. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2192-6 · Cited by 41

Inter-heterogeneity and intra-heterogeneity of αvβ3 in non-small cell lung cancer and small cell lung cancer patients as revealed by 68Ga-RGD2 PET imaging

Kang, F., Wang, Z., Li, G., Wang, S., Liu, D., Zhang, M., Zhao, M., Yang, W., & Wang, J. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3696-2 · Cited by 41

Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients

Cui, J., Wang, L., Zhu, T., Gong, W., Zhou, H., Liu, Z., & Yin, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-05246-8 · Cited by 41

Lung adenocarcinoma with intraoperatively diagnosed pleural seeding: Is main tumor resection beneficial for prognosis?

Li, C., Kuo, S., Hsu, H., Lin, M., & Chen, J. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.09.162 · Cited by 41

Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: A literature-based meta-analysis of randomized studies

Mörth, C., & Valachis, A. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.015 · Cited by 40

Toward Understanding the Antitumor Effects of Water-Soluble Fullerene Derivatives on Lung Cancer Cells: Apoptosis or Autophagy Pathways?

Wong, C., Zhilenkov, A. V., Kraevaya, O. A., Mishchenko, D. V., Troshin, P. A., & Hsu, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00652 · Cited by 40

Computed tomography–guided lung biopsy: a randomized controlled trial of low-dose versus standard-dose protocol

Fu, Y., Li, G., Xu, Q.-S., Shi, Y., Wang, C., & Wang, T. (2019) · European Radiology · doi:10.1007/s00330-019-06464-6 · Cited by 40

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Cox, M. L., Yang, C. J., Speicher, P. J., Anderson, K. L., Fitch, Z. W., Gu, L., Davis, R. P., Wang, X., D’Amico, T. A., Hartwig, M. G., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.003 · Cited by 39

Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers

Horne, Z. D., Richman, A. H., Dohopolski, M. J., Clump, D. A., Burton, S. A., & Heron, D. E. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.10.014 · Cited by 39

Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer

Park, C., Kim, J.-E., Kim, M., Kho, B., Park, H.-Y., Kim, T.-O., Shin, H., Cho, H.-J., Choi, Y. D., Oh, I., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02944-w · Cited by 39

Management of stage IIIA (N2) non–small cell lung cancer: A transatlantic perspective

Rocco, G., Nason, K. S., Brunelli, A., Varela, G., Waddell, T. K., & Jones, D. R. (2016) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2016.01.035 · Cited by 39

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer

Yap, T. A., Macklin-Doherty, A., & Popat, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.014 · Cited by 38

Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer

Shen, C., Kehl, K. L., Zhao, B., Simon, G. R., Zhou, S., & Giordano, S. H. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.11.002 · Cited by 38

Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer

Reckamp, K. L. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0046 · Cited by 28

Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment

Aisner, D. L., & Riely, G. J. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.5020 · Cited by 39

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation

Vigneswaran, J., Tan, Y. C., Murgu, S. D., Won, B. M., Patton, K. A., Villaflor, V. M., Hoffman, P. C., Hensing, T. A., Hogarth, D. K., Malik, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7739 · Cited by 27

How and when to use genetic markers for nonsmall cell lung cancer

Lazarus, D. R., & Ost, D. E. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328362075c · Cited by 17

Reflex Testing for Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Fluorescence In Situ Hybridization in Non–Small Cell Lung Cancer

Mino-Kenudson, M. A., & Mark, E. J. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2011-0029-rai.1 · Cited by 33